{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:39:56Z","timestamp":1788349196199,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T00:00:00Z","timestamp":1393027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-244x-14-52","type":"journal-article","created":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T02:01:48Z","timestamp":1393034508000},"source":"Crossref","is-referenced-by-count":12,"title":["Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate"],"prefix":"10.1186","volume":"14","author":[{"given":"Jennifer Kern","family":"Sliwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,22]]},"reference":[{"issue":"12","key":"1566_CR1","first-page":"1821","volume":"75","author":"SH Schultz","year":"2007","unstructured":"Schultz SH, North SW, Shields CG: Schizophrenia: a review. Am Fam Physician. 2007, 75 (12): 1821-1829.","journal-title":"Am Fam Physician"},{"issue":"1","key":"1566_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/PCC.v10n0104","volume":"10","author":"G Balf","year":"2008","unstructured":"Balf G, Stewart TD, Whitehead R, Baker RA: Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry. 2008, 10 (1): 15-24. 10.4088\/PCC.v10n0104.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"1566_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/070674370104600308","volume":"46","author":"RS McIntyre","year":"2001","unstructured":"McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001, 46 (3): 273-281.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"1566_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1176\/appi.psy.41.4.369","volume":"41","author":"PE Croarkin","year":"2000","unstructured":"Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associated with risperidone treatment?. Psychosomatics. 2000, 41 (4): 369-370. 10.1176\/appi.psy.41.4.369.","journal-title":"Psychosomatics"},{"issue":"15","key":"1566_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00002018-200225150-00005","volume":"25","author":"K Hedenmalm","year":"2002","unstructured":"Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O: Glucose intolerance with atypical antipsychotics. Drug Saf. 2002, 25 (15): 1107-1116. 10.2165\/00002018-200225150-00005.","journal-title":"Drug Saf"},{"issue":"2","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","volume":"160","author":"JP Lindenmayer","year":"2003","unstructured":"Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003, 160 (2): 290-296. 10.1176\/appi.ajp.160.2.290.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80 (1): 19-32. 10.1016\/j.schres.2005.07.014.","journal-title":"Schizophr Res"},{"issue":"6","key":"1566_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/YIC.0b013e32834a5bf6","volume":"26","author":"B Falissard","year":"2011","unstructured":"Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M: The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011, 26 (6): 291-302. 10.1097\/YIC.0b013e32834a5bf6.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","volume":"61","author":"A Tschoner","year":"2007","unstructured":"Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF: Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007, 61 (8): 1356-1370. 10.1111\/j.1742-1241.2007.01416.x.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1566_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2337\/diacare.26.5.1597","volume":"26","author":"ME Lean","year":"2003","unstructured":"Lean ME, Pajonk FG: Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003, 26 (5): 1597-1605. 10.2337\/diacare.26.5.1597.","journal-title":"Diabetes Care"},{"issue":"8","key":"1566_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","volume":"161","author":"SR Marder","year":"2004","unstructured":"Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004, 161 (8): 1334-1349. 10.1176\/appi.ajp.161.8.1334.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1566_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27 (2): 596-601.","journal-title":"Diabetes Care"},{"key":"1566_CR13","volume-title":"INVEGA\u00ae SUSTENNA\u00ae paliperidone palmitate prescribing information September 2011","author":"INVEGA\u00ae SUSTENNA\u00ae Prescribing Information","year":"2011","unstructured":"INVEGA\u00ae SUSTENNA\u00ae Prescribing Information: INVEGA\u00ae SUSTENNA\u00ae paliperidone palmitate prescribing information September 2011. 2011, (Accessed on 27 April 2012) Available at: http:\/\/www.invegasustenna.com\/important-product-information"},{"issue":"2\u20133","key":"1566_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M: Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010, 116 (2\u20133): 107-117.","journal-title":"Schizophr Res"},{"issue":"5","key":"1566_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/0269881110372817","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2010, 25 (5): 685-697.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1566_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28 (7): 412-419. 10.1007\/BF00280883.","journal-title":"Diabetologia"},{"issue":"6","key":"1566_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care. 2004, 27 (6): 1487-1495. 10.2337\/diacare.27.6.1487.","journal-title":"Diabetes Care"},{"issue":"3","key":"1566_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/0897190012442220","volume":"25","author":"UA Kagal","year":"2012","unstructured":"Kagal UA, Torgal SS, Patil NM, Malleshappa A: Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study. J Pharm Pract. 2012, 25 (3): 368-373. 10.1177\/0897190012442220. Epub 2012","journal-title":"J Pharm Pract"},{"issue":"5","key":"1566_CR19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","volume":"17","author":"P Pramyothin","year":"2010","unstructured":"Pramyothin P, Khaodhiar L: Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010, 17 (5): 460-466. 10.1097\/MED.0b013e32833de61c.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"1566_CR20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L\u2019Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006, 163 (10): 1821-1825. 10.1176\/appi.ajp.163.10.1821.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1566_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007, 164 (7): 1050-1060. 10.1176\/appi.ajp.164.7.1050.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1566_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose\u2013response study. Int Clin Psychopharmacol. 2010, 25 (5): 247-256. 10.1097\/YIC.0b013e32833948fa.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"1566_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010, 13 (5): 635-647. 10.1017\/S1461145709990988.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79","volume":"35","author":"HA Nasrallah","year":"2010","unstructured":"Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010, 35 (10): 2072-2082. 10.1038\/npp.2010.79.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1566_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010, 30 (3): 235-244. 10.1097\/JCP.0b013e3181dd3103.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A Ucok","year":"2008","unstructured":"Ucok A, Gaebel W: Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008, 7 (1): 58-62.","journal-title":"World Psychiatry"},{"issue":"Suppl 7","key":"1566_CR27","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001, 62 (Suppl 7): 22-31.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1566_CR28","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.clinthera.2008.12.020","volume":"30","author":"R Emsley","year":"2008","unstructured":"Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008, 30 (12): 2378-2386. 10.1016\/j.clinthera.2008.12.020.","journal-title":"Clin Ther"},{"issue":"1","key":"1566_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1744-859X-12-22","volume":"12","author":"M Markowitz","year":"2013","unstructured":"Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L: Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Ann Gen Psychiatry. 2013, 12 (1): 22-10.1186\/1744-859X-12-22.","journal-title":"Ann Gen Psychiatry"},{"key":"1566_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-12-26","volume":"12","author":"D Coppola","year":"2012","unstructured":"Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012, 12: 26-10.1186\/1471-244X-12-26. doi:10.1186\/1471-1244X-1112-1126","journal-title":"BMC Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-14-52\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T08:22:47Z","timestamp":1498119767000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-14-52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-14-52","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,22]]},"article-number":"52"}}